MedTrace Logo

The Effects of an Infant Formula Containing Hydrolysed Proteins on Growth and Tolerance in Healthy Term Infants

NCT05757323 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 345

Last updated 2023-09-22

No results posted yet for this study

Summary

In this clinical trial, weight gain (primary objective), and additional anthropometry (secondary objectives), of infants exclusively consuming a hydrolysed protein-based infant formula were evaluated and compared to a standard intact protein-based formula over a period of at least three months, until the age of 17 weeks.

Conditions

  • Growth

Interventions

OTHER

infant formula based on hydrolyzed protein

infant formula based on hydrolysed protein

OTHER

infant formula based on intact protein

infant formula based on intact protein

Sponsors & Collaborators

  • FrieslandCampina

    lead INDUSTRY

Principal Investigators

  • Yannis Manios, Prof · Harokopio University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
5 Days
Max Age
28 Days
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-06
Primary Completion
2022-10-24
Completion
2022-10-24

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05757323 on ClinicalTrials.gov